Stem cell collection in patients with de novo multiple myeloma treated with the combination of bortezomib and dexamethasone before autologous stem cell transplantation according to IFM 2005–01 trial

[1]  M. Mohty,et al.  Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  M. Baccarani,et al.  A Phase III Study of Double Autotransplantation Incorporating Bortezomib-Thalidomide-Dexamethasone (VTD) or Thalidomide-Dexamethasone (TD) for Multiple Myeloma: Superior Clinical Outcomes with VTD Compared to TD. , 2009 .

[3]  D. Esseltine,et al.  High Response Rates and Encouraging Time-to-Event Data with Lenalidomide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Final Results of a Phase I/II Study. , 2009 .

[4]  K. Anderson,et al.  Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. , 2009, Blood.

[5]  David E. Irwin,et al.  Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. , 2009, Blood.

[6]  B. Barlogie,et al.  International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100) , 2009, Leukemia.

[7]  D. Esseltine,et al.  Bortezomib, doxorubicin and dexamethasone (PAD) front‐line treatment of multiple myeloma: updated results after long‐term follow‐up , 2008, British journal of haematology.

[8]  A. Bhandoola,et al.  The earliest thymic progenitors for T cells possess myeloid lineage potential , 2008, Nature.

[9]  S. Paolini,et al.  Farnesyltransferase inhibition in hematologic malignancies: the clinical experience with tipifarnib. , 2008, Clinical advances in hematology & oncology : H&O.

[10]  A. Oriol,et al.  Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  R. Arceci,et al.  Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  B. Pégourié,et al.  Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. , 2006, Haematologica.

[13]  S. Jagannath,et al.  Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma , 2005, British journal of haematology.